Department of Radiology, Nuclear Medicine Division, The Methodist Hospital Research Institute, 6565 Fannin St, MB1-066, Houston, TX 77030, USA.
AJR Am J Roentgenol. 2011 Aug;197(2):318-24. doi: 10.2214/AJR.11.6797.
A theranostic system integrates some form of diagnostic testing to determine the presence of a molecular target for which a specific drug is intended. Molecular imaging serves this diagnostic function and provides powerful means for noninvasively detecting disease. We briefly review the paradigms rooted in nuclear medicine and highlight recent advances in this field. We also explore how nanometer-sized complexes, called nanomedicines, present an excellent theranostic platform applicable to both drug discovery and clinical use.
For imagers, molecular theranostics represents a powerful emerging platform that intimately couples targeted therapeatic entities with noninvasive imaging that yields information on the presence of defined molecular targets before, during, and after cognate therapy.
治疗诊断系统将某种形式的诊断测试集成在一起,以确定特定药物针对的分子靶标是否存在。分子成像具有这种诊断功能,并为非侵入性检测疾病提供了强大的手段。我们简要回顾了源于核医学的范例,并强调了该领域的最新进展。我们还探讨了纳米级复合物(称为纳米药物)如何成为适用于药物发现和临床应用的出色治疗诊断平台。
对于成像者来说,分子治疗诊断代表了一个强大的新兴平台,它将靶向治疗实体与无创成像紧密结合在一起,在同源治疗之前、期间和之后提供关于定义的分子靶标的存在的信息。